MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$77,905K
EPS
-$2.02
Unit: Thousand (K) dollars

Income Statement
2025-12-31
Research and development
59,990
General and administrative
24,124
Total operating expenses
84,114
Loss from operations
-84,114
Interest income
6,479
Other expense, net
-270
Total other income, net
6,209
Net loss
-77,905
Basic EPS
-2.02
Diluted EPS
-2.02
Basic Average Shares
38,509,281
Diluted Average Shares
38,509,281
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Interest income$6,479K Net loss-$77,905K Total other income,net$6,209K Other expense, net-$270K Loss from operations-$84,114K Total operatingexpenses$84,114K Research and development$59,990K General andadministrative$24,124K

Acrivon Therapeutics, Inc. (ACRV)

Acrivon Therapeutics, Inc. (ACRV)